Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
A phase II double-blind placebo-controlled parallel group clinical trial that will randomize
90 subjects to investigate whether pregabalin (PGB) combined with Lofexidine (LFX) can reduce
opioid withdrawal-related subjective effects, and investigate, whether the PGB/LFX
combination can increase the proportion of patients with an opioid use disorder (OUD) who
complete detoxification and transition to antagonist treatment with extended-release
injectable naltrexone (XR-NTX).